Across-sectional study was performed of pediatric hematology-oncology patients who received vancomycin; use was compared to the Centers for Disease Control and Prevention (CDC) recommendations for vancomycin use. Thirty-seven patients received 308 doses of vancomycin. AR patients initially received vancomycin as empirical therapy; 100% of this use was not consistent with the CDC recommendations.
Hopkins HA, Sinkowitz-Cochran RL, Rudin BA, Keyserling HL, Jarvis WR
Infect Control Hosp Epidemiol 2000 Jan;21(1):48-50